These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 27702574)

  • 21. The chaperonin TRiC controls polyglutamine aggregation and toxicity through subunit-specific interactions.
    Tam S; Geller R; Spiess C; Frydman J
    Nat Cell Biol; 2006 Oct; 8(10):1155-62. PubMed ID: 16980959
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hsp70 and hsp40 chaperones can inhibit self-assembly of polyglutamine proteins into amyloid-like fibrils.
    Muchowski PJ; Schaffar G; Sittler A; Wanker EE; Hayer-Hartl MK; Hartl FU
    Proc Natl Acad Sci U S A; 2000 Jul; 97(14):7841-6. PubMed ID: 10859365
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Osmolytes modulate polyglutamine aggregation in a sequence dependent manner.
    Saha I; Singh V; Burra G; Thakur AK
    J Pept Sci; 2018 Aug; 24(8-9):e3115. PubMed ID: 30062707
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polyglutamine aggregation in Huntington's disease and spinocerebellar ataxia type 3: similar mechanisms in aggregate formation.
    Seidel K; Siswanto S; Fredrich M; Bouzrou M; Brunt ER; van Leeuwen FW; Kampinga HH; Korf HW; Rüb U; den Dunnen WF
    Neuropathol Appl Neurobiol; 2016 Feb; 42(2):153-66. PubMed ID: 26095752
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chaperonin TRiC promotes the assembly of polyQ expansion proteins into nontoxic oligomers.
    Behrends C; Langer CA; Boteva R; Böttcher UM; Stemp MJ; Schaffar G; Rao BV; Giese A; Kretzschmar H; Siegers K; Hartl FU
    Mol Cell; 2006 Sep; 23(6):887-97. PubMed ID: 16973440
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of protein misfolding/aggregation using polyglutamine binding peptide QBP1 as a therapy for the polyglutamine diseases.
    Popiel HA; Takeuchi T; Burke JR; Strittmatter WJ; Toda T; Wada K; Nagai Y
    Neurotherapeutics; 2013 Jul; 10(3):440-6. PubMed ID: 23504628
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Huntingtin aggregation and toxicity in Huntington's disease.
    Bates G
    Lancet; 2003 May; 361(9369):1642-4. PubMed ID: 12747895
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The C-terminal α-helices of mammalian Hsc70 play a critical role in the stabilization of α-synuclein binding and inhibition of aggregation.
    Chaari A; Eliezer D; Ladjimi M
    Int J Biol Macromol; 2016 Feb; 83():433-41. PubMed ID: 26601760
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Toward therapeutic targets for SCA3: Insight into the role of Machado-Joseph disease protein ataxin-3 in misfolded proteins clearance.
    Li X; Liu H; Fischhaber PL; Tang TS
    Prog Neurobiol; 2015 Sep; 132():34-58. PubMed ID: 26123252
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Selective degradation of expanded polyglutamine proteins by their specific recognition with QBP1].
    Nagai Y; Nukina N
    Rinsho Shinkeigaku; 2011 Nov; 51(11):1108-10. PubMed ID: 22277499
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ubiquitin conjugating enzymes participate in polyglutamine protein aggregation.
    Howard RA; Sharma P; Hajjar C; Caldwell KA; Caldwell GA; du Breuil R; Moore R; Boyd L
    BMC Cell Biol; 2007 Jul; 8():32. PubMed ID: 17663792
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Suppression of polyglutamine-induced toxicity in cell and animal models of Huntington's disease by ubiquilin.
    Wang H; Lim PJ; Yin C; Rieckher M; Vogel BE; Monteiro MJ
    Hum Mol Genet; 2006 Mar; 15(6):1025-41. PubMed ID: 16461334
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A chaperome subnetwork safeguards proteostasis in aging and neurodegenerative disease.
    Brehme M; Voisine C; Rolland T; Wachi S; Soper JH; Zhu Y; Orton K; Villella A; Garza D; Vidal M; Ge H; Morimoto RI
    Cell Rep; 2014 Nov; 9(3):1135-50. PubMed ID: 25437566
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chaperone-like activity of high-mobility group box 1 protein and its role in reducing the formation of polyglutamine aggregates.
    Min HJ; Ko EA; Wu J; Kim ES; Kwon MK; Kwak MS; Choi JE; Lee JE; Shin JS
    J Immunol; 2013 Feb; 190(4):1797-806. PubMed ID: 23303669
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Co-chaperone CHIP promotes aggregation of ataxin-1.
    Choi JY; Ryu JH; Kim HS; Park SG; Bae KH; Kang S; Myung PK; Cho S; Park BC; Lee DH
    Mol Cell Neurosci; 2007 Jan; 34(1):69-79. PubMed ID: 17127076
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modulation of neurodegeneration by molecular chaperones.
    Muchowski PJ; Wacker JL
    Nat Rev Neurosci; 2005 Jan; 6(1):11-22. PubMed ID: 15611723
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multi-domain misfolding: understanding the aggregation pathway of polyglutamine proteins.
    Saunders HM; Bottomley SP
    Protein Eng Des Sel; 2009 Aug; 22(8):447-51. PubMed ID: 19589877
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of chain length on the aggregation of model polyglutamine peptides: molecular dynamics simulations.
    Marchut AJ; Hall CK
    Proteins; 2007 Jan; 66(1):96-109. PubMed ID: 17068817
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protein-misfolding diseases and chaperone-based therapeutic approaches.
    Chaudhuri TK; Paul S
    FEBS J; 2006 Apr; 273(7):1331-49. PubMed ID: 16689923
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The potential of indole and a synthetic derivative for polyQ aggregation reduction by enhancement of the chaperone and autophagy systems.
    Lin CH; Wu YR; Kung PJ; Chen WL; Lee LC; Lin TH; Chao CY; Chen CM; Chang KH; Janreddy D; Lee-Chen GJ; Yao CF
    ACS Chem Neurosci; 2014 Oct; 5(10):1063-74. PubMed ID: 25197952
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.